Publications

PUBLICATIONS and PATENTS, 2005- :

Papers:

32. Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinol in parrot plasma.
Catherine M. Gilbert, Ross P. McGeary, Lucio J. Filippich, Ross L.G. Norris, Bruce G. Charles.
Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 826, 273-276.

33. Facile Synthesis of Rhodamine Esters Using Acetyl Chloride in Alcohol Solution.
Justin A. Ross, Benjamin P. Ross, Helina Rubinsztein-Dunlop, Ross P. McGeary.
Synthetic Communications, 2006, 36, 1745-1750.

34. Saponins from Quillaja saponaria Molina: isolation, characterization and ability to form immuno stimulatory complexes (ISCOMs).
Lam H. Pham, Benjamin P. Ross, Ross P. McGeary, P. Nicholas Shaw, Amitha K. Hewavitharana, Nigel M. Davies.
Current Drug Delivery, 2006, 3, 389-397.

35. Pharmacokinetics of doxorubicinol in dogs.
Catherine M. Gilbert, Lucio J. Filippich, Ross P. McGeary, Bruce G. Charles.
Journal of Veterinary Pharmacology and Therapeutics, 2006, 29, 433-435.

36. Determination of the Anomeric Configurations of 2,3,4,6-Tetra-O-Acetyl-D-Mannopyranosyl Azide.
Kelly L. Cosgrove, Paul V. Bernhardt, Benjamin P. Ross and Ross P. McGeary.
Australian Journal of Chemistry, 2006, 59, 473-476.

37. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Catherine M. Gilbert, Lucio J. Filippich, Ross P. McGeary, Bruce G. Charles.
Research in Veterinary Science, 2007, 83, 123-129.

38. Vaccine delivery utilizing liposaccharides.
Simerska, P, Moyle, PM, Zhong, W, McGeary, R, Abdel-Aal, AB, Good, MF and Toth, I
Biopolymers, 2007, 88, 534.

39. Synthesis and Polymerization Studies of Organic-Soluble Eumelanins.
Kirsten J. Lawrie, Paul Meredith and Ross P. McGeary.
Photochemistry and Photobiology, 2008, 84, 632-8.

40. The development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
Pavla Simerska, Abu-Baker M. Abdel-Aal, Yoshio Fujita, Peter M. Moyle, Ross P. McGeary, Michel R. Batzloff, Colleen Olive, Michael F. Good, Istvan Toth.
Journal of Medicinal Chemistry, 2008, 51, 1447-52.

41. Suramin: Clinical Uses and Structure-Activity Relationships
Ross P. McGeary, Andrew J. Bennett, Quoc B. Tran, Kelly L. Cosgrove and Benjamin P. Ross,
Mini-Reviews in Medicinal Chemistry, 2008, 8, 1384-94.

42. An Efficient and Solvent-Free Synthesis of Mixed Ortho Esters
Kelly L, Cosgrove and Ross P. McGeary
Synlett, 2008, 2425-2428.

43. Inhibition of purple acid phosphatase with a-alkoxynaphthylmethylphosphonic acids.
Ross P. McGeary, Peter Vella, Jeffrey Y. W. Mak, Luke W. Guddat and Gerhard Schenk
Bioorganic & Medicinal Chemistry Letters, 2009, 19, 163-166.

44. Synthesis of Nickel-Chelating Fluorinated Lipids for Protein Monolayer Crystallizations
Waleed M. Hussein, Benjamin P. Ross, Michael J. Landsberg, Daniel Levy, Ben Hankamer, Ross P. McGeary
Journal of Organic Chemistry, 2009, 74, 1473-1479.

45. An "inside-out" approach to suramin analogues
Ross P. McGeary, Andrew J. Bennett, Quoc B. Tran, Johannes Prins and Benjamin P. Ross
Tetrahedron, 2009, 65, 3990-3997

46. Identification of novel target sites and an inhibitor of the dengue virus E protein
Ragothaman Yennamalli, Naidu Subbarao, Thorsten Kampmann, Ross P McGeary, Paul R Young, Bostjan Kobe,
Journal of Computer-Aided Molecular Design, 2009, 23, 333-341.

47. Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs)
Hoang L. Pham, Benjamin P. Ross, Ross P. McGeary, P. Nicholas Shaw and Nigel M. Davies,
International Journal of Pharmaceutics, 2009, 376, 123-133.

48. A Convenient Triisobutylaluminium (TIBAL)-Promoted Johnson-Claisen Approach to g,d-Unsaturated Alcohols
Kelly L, Cosgrove and Ross P. McGeary
Synlett, 2009, 1749-1752.

49. Synthetic Approaches to Functionalized Lipids for Protein Monolayer Crystallizations
Waleed M. Hussein, Benjamin P. Ross, Michael J. Landsberg, Ben Hankamer and Ross P. McGeary
Current Organic Chemistry, 2009, 13, 1378-1405.

50. Vaccine delivery utilizing liposaccharides
Pavla Simerska, Ross P. McGeary, Abu-Baker M. Abdel-Aal, Peter M. Moyle, Colleen Olive, Michael F. Good, Istvan Toth
Advances in Experimental Medicine and Biology, 2009, 611, 345-6.

51. Tartrate-resistant acid phosphatase, a target for novel anti-osteoporotic chemotherapeutics
Peter Vella, Ross P. McGeary, Lawrence R. Gahan, Gerhard Schenk
Current Enzyme Inhibition, 2010, 6, 118-129.

52. New Methodology for the Conversion of Epoxides to Alkenes
Feng-Ling Wu, Benjamin P. Ross and Ross P. McGeary
European Journal of Organic Chemistry, 2010, 1989-1998.

53. Exploring the versatility of the Johnson-Claisen rearrangement: access to functionally versatile d-ethoxycarbonyl-a,b-unsaturated nitriles
Kelly L. Cosgrove and Ross P. McGeary
Tetrahedron, 2010, 66, 3050-3057.

54. Molecular packing of functionalized fluorinated lipids in Langmuir monolayers
Michael Landsberg, Jeremy Ruggles, Waleed Hussein, Ross McGeary, Ian Gentle and Ben Hankamer
Langmuir, 2010, 26, 18868-18873.

55. Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase
Siti Hajar Mohd-Pahmi, Waleed M Hussein, Gerhard Schenk and Ross P. McGeary
Bioorganic & Medicinal Chemistry Letters, accepted March 9, 2011.

56. The identification of new metallo-b-lactamase inhibitor leads from fragment-based screening
Peter Vella, Waleed M. Hussein, Eleanor W.W. Leung, Daniel Clayton, David L. Ollis, Nataša Mitić, Gerhard Schenk and Ross P. McGeary
Bioorganic & Medicinal Chemistry Letters, In Press, 2011.

Book Chapters:

3. Systemic Antifungal Agents
Ross P. McGeary
Molecular Pathomechanisms and New Trends in Drug Research (Eds. G. Keri and I. Tooth), Harwood Academic Publishers, 2003.

Patents:

1. New methods for the synthesis of cyclic peptides or peptidomimetics, useful for providing compounds with novel biological properties and producing libraries for drug screening
Smythe M L, Meutermans W D F, Bourne G T, McGeary R P
(2000) WO200018790-A; WO200018790-A1; AU9961830-A; EP1115738-A1;JP2002533299-W; AU766495-B

2. New celery seed extract composition produced by supercritical fluid extraction, useful for the treatment and prevention of acute and chronic pain, inflammation and gastrointestinal irritation
Butters D E, Davis C K C, McGeary R P, Powanda M C, Rainsford K D, Whitehouse M W
(2000) WO200040258-A; EP1140125-A; WO200040258-A1; AU200018117-A; EP1140125-A1; US2003206980-A1; AU773482-B2

3. New method of reducing gastric irritation before, during or after introduction of a gastric irritant, preferably non-steroidal anti-inflammatory drugs, comprises administration of active celery seed extract
Butters D E, Davis C K C, McGeary R P, Powanda M C, Rainsford K D, Whitehouse M W
(2002) US6352728-B1

4. New lipid bound mono- or oligo-saccharide core peptide compounds used for treating e.g. cancer, Alzheimer's disease, hypertension and atherosclerosis
Toth I, McGeary R P, West M L, Ramsdale T E
(2002) WO200232963-A; WO200232963-A1; AU200195287-A

5. New active celery seed extract, useful for treating inflammation, pain and gastrointestinal irritation, is produced by supercritical fluid extraction of ethanolic extract of celery seed
Butters D E, Davis C K C, McGeary R P, Powanda M C, Rainsford K D, Whitehouse M W
(2002) US2002081343-A1; US6576274-B2; US6761913-B2

6. New amide-linked mono, di and tri-saccharide-lipoamino acid complex useful in drug delivery
Toth I, Falconer R, De Cruz S E, McGeary R P, Ross B P
(2002) WO200253572-A; WO200253572-A1; AU2002216843-A1; US2004176281-A1

7. New amino acid derivatives useful for the treatment of inflammatory disease or condition e.g. rheumatic arthritis
Reid R C, Clark C I, Hansford K, Stoermer M J, McGeary R P, Fairlie D P, Schafer K E
(2002) WO200208189-A; WO200208189-A1; AU200172234-A; EP1309552-A1; JP2004503604-W; US2004033995-A1

8. Differentiation modulating agents and uses therefore
Prins J B, Hutley L J, McGeary R P
(2005) WO2005065686

9. Method for treating or preventing obesity with adipogenesis-inhibiting agents which antagonize fibroblast growth factor signaling
Prins J B, Hutley L J, McGeary R P
(2005) US20050282733-A1; WO2004003179-A1; AU2009251219-A1

10. Oral drug delivery systems comprising ionic complexes including mono- or oligosaccharide, lipidic moiety, and optionally a linker and/or a spacer.
Toth I, Falconer R, De Cruz S E, McGeary R P, Ross B P
(2007) US7312194-B2; US20040176281-A1; WO2002053572-A1
[Continuation-in-part of Appl. No. PCT/AU02/5].

11. Synthesis of cyclic peptides
Smythe, Mark Leslie; Meutermans, Wim Denis Frans; Bourne, Gregory Thomas; McGeary, Ross Peter
(2009) US 07589170